Abstract-Inflammatory cytokines are necessary for an acute response to injury and the progressive healing process. However, when this acute response does not resolve and becomes chronic, the same proteins that once promoted healing then contribute to chronic inflammatory pathologies, such as atherosclerosis. OPN (Osteopontin) is a secreted matricellular cytokine that signals through integrin and CD44 receptors, is highly upregulated in acute and chronic inflammatory settings, and has been implicated in physiological and pathophysiologic processes. Evidence from the literature suggests that OPN may fit within the Goldilocks paradigm with respect to cardiovascular disease, where acute increases are protective, attenuate vascular calcification, and promote postischemic neovascularization. In contrast, chronic increases in OPN are clinically associated with an increased risk for a major adverse cardiovascular event, and OPN expression is a strong predictor of cardiovascular disease independent of traditional risk factors. With the recent finding that humans express multiple OPN isoforms as the result of alternative splicing and that these isoforms have distinct biologic functions, future studies are required to determine what OPN isoform(s) are expressed in the setting of vascular disease and what role each of these isoforms plays in vascular disease progression. This review aims to discuss our current understanding of the role(s) of OPN in vascular disease pathologies using evidence from in vitro, animal, and clinical studies. Where possible, we discuss what is known about OPN isoform expression and our understanding of OPN isoform contributions to cardiovascular disease pathologies.
O PN (osteopontin) is a secreted multifunctional glycophosphoprotein that plays important roles in physiological and pathophysiological processes. As the name implies, OPN is produced by cells involved in bone morphogenesis, and 1 major physiological role of OPN is in the control of biomineralization and calcification. 1 In this brief review, we aim to examine OPN functions specifically in the vasculature and additional physiological functions of OPN have been reviewed previously. Under physiological conditions, circulating and tissue OPN expression levels in the vasculature are low but are important for normal arterial physiology. 2 Indeed, these low OPN expression levels were shown to be necessary for normal arterial mechanics, and it is also known that OPN acts as a physiological inhibitor of vascular calcification. In response to injury, OPN is acutely upregulated and promotes cell adhesion, proliferation, migration, and survival to aid in the healing process, but expression typically resolves over time. 3, 4 Vascular cell types that upregulate and secrete OPN include endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages. 3, 5 In contrast, OPN expression levels remain elevated in several disease pathologies with a chronic inflammatory component including Crohn disease, multiple sclerosis and other autoimmune disorders, wound healing, various cancer types, and cardiovascular disease (CVD) pathologies.
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More recently, there has been considerable interest in OPN as a biomarker for various pathological conditions. Peripheral blood and cerebrospinal fluid concentrations of OPN are elevated in multiple sclerosis patients 6 and neurodegenerative diseases like Alzheimer. 7 There is also interest in OPN as a prognostic and diagnostic marker for diseases including, but not limited to, multiple sclerosis, 6 coronary artery disease, 8 and several cancer types 9 with a recent specific focus on individual OPN isoforms for this purpose. 10, 11 Increased OPN expression is also a strong predictor of outcomes in patients with calcific aortic valve disease 12, 13 and ischemic vascular pathologies, including stroke, 14, 15 myocardial infarction, [16] [17] [18] and peripheral artery disease. 19, 20 While interest in OPN as a potential biomarker increases, there is a large body of evidence that clearly establishes that OPN is specific driver of cellular functions that impact physiological and pathophysiologic processes in the vascular setting, as discussed in more detail below, and ultimately point to OPN as a potential therapeutic target. 21 In this review, we will examine our current understanding of OPN protein structure and function, regulation of OPN expression, and role(s) of OPN in vascular disease pathologies while introducing what is currently understood about OPN isoform contributions.
Osteopontin Structure and Function
Osteopontin was first described in 1985 by Franzén and Heinegård et al 22 as 1 of 2 sialoproteins derived from bovine bone matrix. Osteopontin was previously identified as SPP1 (secreted phosphoprotein 1), BSP-1 (bone sialoprotein 1), and Eta-1 (early T-lymphocyte activation-1). This plurality of names reflects the range of functions attributable to OPN. As a matricellular protein, OPN differs from the structural extracellular matrix proteins, such as collagen, in that it does not serve a primary structural role. 23 Matricellular proteins do, however, function as modulators of cell-matrix interactions, often achieved by binding to cell-surface receptors, growth factors, proteases, and structural matrix proteins, making them important components of the extracellular matrix environment. 24 Indeed, matricellular proteins like OPN are often induced during tissue remodeling and repair, as well as in disease states. 23 The original members of the matricellular protein family included SPARC (secreted protein acidic and rich in cysteine), TSP-1 (thrombospondin 1), and tenascin-C and has expanded to include CCN proteins (Cyr61, CCN2, CCN3) and OPN. 27 suggested that multiple CD44 binding domains are present in the N-and C-terminal regions of OPN. This same study proposed a potential complex between CD44 variants and integrin receptors because the binding of CD44 variants to OPN was inhibited by anti-β 1 antibodies. 27 OPN has primarily been described as a secreted protein; however, an intracellular form of OPN, made possible by a non-AUG alternative start codon that omits the N-terminal secretion peptide, 28 has been reported in rodents and localizes to the cell membrane where it binds to CD44 to regulate cell migration.
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Post-Translational Modifications of Osteopontin
OPN is a complex protein that is aspartic-acid rich, contains long stretches of negatively charged sequences that bind calcium, and can be cleaved by thrombin and MMPs (matrix metalloproteinases). OPN is subjected to numerous posttranslational modifications (PTMs), including serine/threonine phosphorylation, glycosylation, and tyrosine sulfation, which increase the monomeric molecular weight from the predicted ≈35 kDa to 41 to 75 kDa. 31 A polymeric form of OPN with a mass of >200 kDa can also be generated upon protein transglutamination. 32 Importantly, it has been shown that many of these PTMs regulate and alter OPN function.
Phosphorylation
The OPN sequence contains 36 predicted phosphorylation sites that include serine, threonine, and tyrosine residues. 33 The serine/threonine phosphorylation of OPN has been primarily attributed to a Golgi apparatus casein kinase over casein kinases-1 and -2, 34 identified recently as FAM20C, which phosphorylates numerous secreted proteins with S-x-E motifs. 33, 35 The distinct functional properties of OPN are dependent, in part, on the nature and extent of phosphorylation. Interestingly, Christensen et al 36 demonstrated that the degree of OPN phosphorylation can be cell-type specific, where they showed an osteoblast cell line (MC3T3-E1) added 21 phosphates, whereas only ≈4 phosphates were added by a ras-transformed fibroblast cell line (275-3-2). This same study demonstrated that fibroblast-derived OPN (low phosphorylation) mediated greater adherence of human breast cancer cells than the highly phosphorylated osteoblast-derived OPN. 36 Therefore, OPN generated by different cell types and, thus, differentially phosphorylated may exhibit different biologic effects. Indeed, phosphorylated OPN can inhibit calcification in cultured human VSMCs, which was not observed with recombinant bacterial OPN that lacks PTMs. 37 Additionally, OPN phosphorylation is necessary for IL (interleukin)-12 expression in macrophages, whereas dephosphorylation abolishes this effect. 38 The Glycosylation influences the folding structure, proteolytic cleavage and, subsequently, the functional properties of OPN. 39 Indeed, deletion of multiple O-glycosylation sites in OPN affects cell adhesion activity and phosphorylation state. 40, 41 Similarly, lung cancer cells that stably expressed an OPN mutant lacking 3 O-glycosylation sites exhibit a reduction in cell growth and migration. 42 To our knowledge, N-glycosylation has so far only been reported in rat and human bone OPN 43, 44 and no apparent N-linked oligosaccharides were found in human milk OPN, suggesting that this form of glycosylation may be tissue specific.
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Transglutamination
Osteopontin can serve as a substrate for TG2 (transglutaminase 2). 45 TG2 is a ubiquitously expressed calcium-dependent enzyme that catalyzes cross-linking of glutamine and lysine residues. 45, 46 TG2 cross-linking of OPN can be both inter and intramolecular.
47 TG2-mediated OPN polymerization alters both conformation and function, which is attributed to the exposure a new integrin binding site that allows polymeric OPN to bind the α 9 β 1 receptor independent of the SVVYGLR sequence. 48 Other in vitro studies show that polymeric OPN displays increased collagen type I binding affinity 49 and promotes enhanced cell adhesion and migration compared with monomeric OPN. 45, 50 The significance of OPN polymerization in vivo was highlighted by Nishimichi et al, 32 who demonstrated OPN polymerization is required for neutrophil recruitment. Originally, 2 TG2 reactive glutamine (Gln) residues were described in bovine exon 4, Gln34 and Gln36, 51 which correspond to Gln50 and Gln52 in OPNa when designating the initial methionine (Met) residue as aa 1 (amino acid numbers identified in this review are identified using the initial methionine (Met) residue as aa 1 and, therefore, differ from some publications in which the first residue after the 16 aa signal peptide is cleaved off and aa 17 Isoleucine is referred to as aa 1). However, OPN was recently reported to have 12 TG2 reactive residues, with Gln34, Gln42, Gln193, and Gln248 (corresponding to Gln50, Gln58, Gln209, and Gln264 in OPNa) exhibiting the highest reactivity. 52 This could explain why polymerization of OPNc, a splice variant lacking exon 4 and 2 glutamine residues, could still be observed with high TG2 concentrations. 168 motif, just C-terminal to the RGD site, also allows OPN to interact with integrin receptors, including α 4 β 1 , α 9 β 1 , and α 4 β 7 integrin receptors. 53 Recently, it was shown that phosphorylation of the C-terminal fragment could inhibit OPN binding to α v β 3 . 54 This could potentially explain the conflicting findings by various studies suggesting that thrombin cleavage was not a prerequisite for adhesion to α v β 3 , α v β 5 , and α v β 6 as they could bind equally well to full-length OPN or to the RGD sequence at its N-terminal end. 25 Several members of the MMP family have also been reported to cleave OPN at various sites. These include MMP-2, MMP-3, MMP-7, MMP-9, and MMP-12. Interestingly, cleavage of OPN by MMP-3 and MMP-7 within the SVVGLR motif sequence interferes with α 4 β 1 and α 9 β 1 binding. 25, 55 Evidence points to OPN fragments generated by thrombin and MMP cleavage having important pathophysiological functions. For instance, the N-terminal OPN fragment is associated with greater degrees of inflammation in carotid plaques in patients with hypertension. 56 Additionally, the thrombin-cleaved N-terminal fragment with SVVYGLR motif promotes synthesis of collagen type III in cardiac fibrosis. 57 And finally, several in vitro studies have shown that the N-terminal fragment of OPN, rather than full-length OPN, promotes adhesion because of a conformational change that increases its binding activity. 
Osteopontin Isoforms
Humans express 5 OPN isoforms because of alternative splicing of a single SPP1 mRNA transcript to generate: (1) fulllength OPN, known as OPNa (NP_001035147.1), (2) OPNb, which lacks exon 5 (NP_000573.1), (3) OPNc, which lacks exon 4 (NP_001035149.1), (4) OPN4, which lacks exons 4 and 5 (NP_001238758.1), and (5) OPN5, which contains an extra exon because of the retention of a portion of intron 3 (NP_001238759.1). Whether OPN4 and OPN5 are translated to protein remains to be determined; therefore, in this review, we focus on OPNa, OPNb, and OPNc (Figure) . OPN splice variants were first described in glioma cells, 58 are differentially expressed, and display isoform-specific biologic functions. The RGD and SVVYGLR integrin receptor binding domains and the CD44 binding domain are conserved across all 3 isoforms. Despite intact receptor binding domains, OPN isoforms clearly exhibit different intrinsic biological functions. 59, 60 Isoforms differ in that OPNb lacks 3 serine/threonine residues and 1 glutamine residue because of deletion of exon 5, whereas OPNc lacks 2 tyrosine, 2 serine/threonine, and 3 glutamine residues because of deletion of exon 4. Whether these missing exons lend to changes in protein folding, as suggested by predictive modeling, 61 or receptor binding remains to be investigated, and additional studies are required to define the molecular mechanisms underlying OPN isoform-specific biological effects. With a growing interest in the roles OPN isoforms may play in cardiovascular physiology and pathophysiology, we will discuss what is established thus far in this review.
Osteopontin in Vascular Physiology and Pathophysiology
Osteopontin in Acute and Chronic Ischemia
Inflammation is a central component of numerous diseases and can promote tissue damage and inhibit healing if unresolved; however, it is also well understood that immune suppression can limit successful tissue regeneration and recovery of homeostasis. Osteopontin is a secreted protein that is highly upregulated in settings of both acute and chronic ischemia and functions, in part, as an inflammatory cytokine that can promote recruitment of multiple inflammatory cell types and, thus, modulate the inflammatory response. In this section, we will discuss OPN and the Goldilocks principle using ischemia-mediated neovascularization as a model because OPN expression is upregulated in response to ischemia in stroke, 14, 15 myocardial infarction, 16, 17 and peripheral artery disease. 19, 20 OPN expression is often upregulated 20-to 50-fold in response to ischemic insult but typically resolves over time in murine models of stroke, 62 myocardial infarction, 63 and hindlimb ischemia. 3, 64 Studies have established that OPN is a clear driver of the immune response in ischemic conditions, demonstrating that OPN is necessary for macrophage infiltration in vivo. 59, 65 Indeed, OPN is required for postischemic neovascularization, 3, 65 and ischemia-induced OPN expression is reactive oxygen species-dependent. 3 More recently, it was established that OPN isoforms have differential effects on macrophage migration and accumulation and arteriogenesis in vivo, where OPNc was the most potent mediator of these processes. 59 With respect to macrophage function, phagocytosis is diminished in OPN −/− macrophages but can be rescued by recombinant OPN. 66 Pharmacological inhibition or genetic ablation of OPN has also been found to greatly impair macrophage infiltration in various models of acute inflammation. 67 Furthermore, OPN induces macrophage migration via interaction of C-terminal fragment with CD44 surface receptors 68 and more recently, via SLAYGLR domain (SVVYGRL in human OPN) with α 4 and α 9 -integrin receptors. 69 Effects of OPN on macrophage polarization remain controversial. Although one group reported OPN knockdown polarizes macrophages toward an M2c subtype, recently accepted as a proregenerative phenotype, 70 another study using OPN −/− macrophages showed no effects on polarization. 71 Similarly, we did not observe differences in OPN −/− macrophage polarization nor did macrophage polarization shift in response to stimulation with purified recombinant human OPN isoforms, suggesting OPN isoforms do not differentially effect polarization of macrophages. 59 One recent study reports that CD206 + macrophages strongly express OPN and suggests that specific macrophage subtypes involved in tissue repair may differentially express OPN, 63 which requires further investigation. Another point that requires further investigation is whether macrophages at different points within the polarization spectrum respond differently to OPN.
Many of the stimuli known to promote OPN expression, including reactive oxygen species, Ang II (angiotensin II), high glucose and low oxygen tension also contribute to chronic vascular inflammation that, when unresolved, promote long-term, chronic expression of OPN. Recently, oxidized LDL (low-density lipoprotein) was also shown to promote proliferation and migration of human coronary artery SMCs via upregulation of OPN and MMP-9. 72 Additionally, hypoxia and hyperglycemia synergistically increase OPN expression in VSMCs. 73 This is in line with clinical findings that show that OPN is highly and chronically upregulated in patients with peripheral artery disease and in patients with type 1 and type 2 diabetes mellitus and several studies establish OPN as a clear predictor of cardiovascular outcomes in these patient populations. [74] [75] [76] [77] Interestingly, a recent study demonstrated that high glucose-mediated OPN expression is mediated, in part, through changes in histone acetylation and methylation regulated by histone deacetylase and histone methyltransferase, respectively, which was reversed by histone methyltransferase inhibition. 78 This suggests that high glucose-mediated OPN expression is regulated in some cells through epigenetic mechanisms; however, further studies are required to determine if this is true in vascular cells. Collectively, these findings point towards OPN as an integral part of the first line immune response to tissue injury and the tissue remodeling processes required for healing. However, in disease states in which the inflammatory process fails to resolve and becomes chronic, OPN may be detrimental, as discussed further below.
Osteopontin in Atherosclerosis and Neointimal Hyperplasia
Atherosclerosis is characterized by a persistent inflammatory response in the vascular wall in response to noxious stimuli, such as hypoxia, endothelial injury, and hyperglycemia. The role of OPN in atherosclerotic plaque progression has been shown in human and murine vascular diseases and was reviewed in detail by Wolak. 79 High concentrations of OPN are observed in human atherosclerotic plaques in the aorta, carotid, and coronary arteries and are primarily expressed in endothelial cells, macrophages, and VSMCs. 5, 80 In a high-fat diet-induced mouse model of atherosclerosis, OPN overexpression significantly increased fatty-streak and mononuclear cell rich lesion formation, as well as decreased levels of IL-10, an anti-inflammatory atheroprotective cytokine. 81 Likewise, Matsui et al 82 reported that OPN −/− mice had significantly smaller atherosclerotic lesions, but this was only true in female OPN −/− mice, and the authors predominantly attributed this to higher triglyceride and total cholesterol levels in male OPN −/− mice. Worth noting, estrogen has been shown to induce OPN expression, 83 whereas testosterone was shown to suppress it. 84 However, there are conflicting reports in the literature of sex differences in OPN expression, which may be disease or context specific, and this requires further investigation. [85] [86] [87] In an Ang II-accelerated model of atherosclerosis and abdominal aortic aneurysm formation, Bruemmer et al 88 showed that a partial or complete lack of OPN protects against atherosclerosis, partially because of reduced inflammatory macrophage accumulation and viability in atherosclerotic lesions. When Zheng et al 89 used a microarray to compare gene expression profiles in normal aortas and tissues from abdominal aortic aneurysm patients, they found that OPN mRNA is upregulated as much as 125-fold. In this same study, the authors demonstrate that stimulation with high doses of OPN (200-500 ng/mL) promotes increased autophagy, 89 whereas lower doses of OPN have prosurvival effects 59, 69, 90 ; however, the source of OPN used in these studies was not disclosed, suggesting that further studies are required to determine if cellular source, dose, PTMs, or isoforms are important for the survival versus autophagy effects of OPN. In clinical studies, increased plasma OPN expression levels are associated with the presence and severity of coronary artery disease. 91, 92 Interestingly, coronary revascularization and Ang II receptor blockers reduce plasma OPN levels, [93] [94] [95] which is in line with in vitro studies that demonstrate that Ang II induces OPN expression.
96,97 Several clinical studies have also independently demonstrated that the use of plasma OPN expression levels alone can predict CVD events, and all-cause mortality commensurate with other atherosclerosis prognostic markers including lipid profile and hs-CRP (high-sensitivity C-reactive protein) in patients with hypertension, type 1 diabetes mellitus, and type 2 diabetes mellitus. 8, 98, 99 In addition to atherogenesis, OPN also contributes to the development of neointimal hyperplasia after vessel revascularization. Clinical studies have shown that higher baseline OPN levels are associated with rapid coronary plaque progress and in-stent restenosis. 100 OPN mRNA and protein were highly expressed during neointimal formation in mouse and human carotid vessels. 5, 101 In a rat carotid artery injury model, blockade of OPN before endothelial denudation by balloon catheter decreases neointimal thickening of the artery. 102 Similarly, a study by Isoda et al 103 demonstrated increased neointimal thickening after femoral artery cuffing in OPN transgenic mice. More recently, OPN was found to be significantly upregulated over the first postoperative week in the porcine venous wall after saphenous-vein artery interposition graft. 104 OPN expression also correlated well with the number of PCNA (proliferating cell nuclear antigen)-positive cells and MMP expression, suggesting OPN is a key regulator of VSMC proliferation and migration. 104 It is well established that mature, differentiated VSMCs can dedifferentiate into a more proliferative, synthetic phenotype during vascular remodeling and OPN seems to downregulate 2 differentiation markers, α-SM actin and calponin in VSMCs. However, neither SM22-α nor tropomyosin marker expression was altered with overexpression of OPN in vitro; hence, further studies will be required to understand the mechanism by which these genes are regulated by OPN.
105
Osteopontin in Vascular Calcification
Vascular calcification was once considered an end-stage, degenerative process of aging. However, calcification is now recognized as an active, tightly-regulated biomineralization process that may be treatable. 106 One proposed major mechanism that drives vascular calcification is the loss of mineral inhibiting factors, such as MGP (matrix G1a) and osteoprotegerin. 107 OPN is also an important inhibitor of mineral deposition in the vascular wall and in cardiac valves. 110 clearly demonstrated that aortic valve leaflets subcutaneously implanted in OPN −/− mice showed accelerated calcification (4-5 fold greater) compared with wild-type mice and, conversely, that increased OPN and carbonic anhydrase II accumulation correlates with calcification regression. These data were corroborated by another study that showed increased calcification of subcutaneously implanted bovine pericardium tissue in OPN −/− mice, which was mitigated by the administration of histidine-fused OPN at the implant site or adsorption of the OPN onto the implant materials. 111 Interestingly, calcification was only reversed by OPN containing a functional RGDmotif and that was adequately phosphorylated. 111 A separate, independent study showed that only phosphorylated OPN can inhibit calcification in cultured human VSMCs. 37 More recently, OPN levels were shown to be elevated in asymptomatic calcific aortic valve disease patients 12 ; however, a separate study from the same group showed this circulating OPN is de-phosphorylated. 13 Importantly, OPN isoforms were differentially expressed during calcific aortic valve disease progression and functioned to inhibit biomineralization but only when phosphorylated. 12 Altogether, these data support that OPN inhibits calcification and promotes dissolution; however, OPN phosphorylation is critical for these effects.
Osteopontin in Hypertension
The vessel wall undergoes remodeling in response to elevated pressure and pulsatile flow. OPN expression is elevated in hypertension, 98 which is mediated, in part, by increased aortic strain and reactive oxygen species production. 112 Indeed, overexpression of catalase in VSMC in vivo reduced mechanical strain mediated OPN expression in hypertensive animals. 112, 113 One of the mechanism by which mechanical strain increases OPN expression in VSMCs is through activation of the phosphatidylinositol-3 kinase/Akt1 (protein kinase B) signaling pathway. 113 Ang II, a peptide hormone that causes vasoconstriction and increases blood pressure, promotes hypertension and has been shown to upregulate OPN expression, 114 in part, via Ang II-mediated increases in reactive oxygen species production. 97, 112, 115 Vessel remodeling in hypertension involves inflammatory cell infiltration, as well as MMP-mediated degradation and reorganization of the extracellular matrix. 116 OPN has been linked to hypertension-related vascular remodeling and inflammatory cell recruitment. Indeed, early macrophage infiltration into the vascular wall in response to hypertension is blunted in OPN −/− mice compared with wild-type animals. 112 Finally, OPN expression levels are significantly higher in plasma and aortic tissues in hypertensive rodents and expression positively correlates with systolic blood pressure, 113 suggesting that OPN could be used as a clinical marker for hypertension-induced vascular remodeling. One such study showed that treatment with Ang II blocker and statins significantly reduces plasma OPN level.
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Clinical Implications and Conclusions
Inflammation is a central component of numerous diseases, and the discovery of inflammatory biomarkers highly predictive of CVD has the potential to improve targeted treatment strategies. Biomarkers are also of great interest because they can be utilized for diagnostic, prognostic, or therapeutic purposes in the clinical setting. 117, 118 As a secreted protein, OPN is of particular interest as a biomarker because of its detectability in body fluids that include plasma, urine, breast milk, and cerebrospinal fluid; thus, OPN is measurable by minimally invasive means, and this allows for rapid repeated measures over time. Recent clinical studies have demonstrated that OPN expression levels are a strong predictor of CVD events and mortality in several patient populations and may prove to be a useful prognostic for disease activity and severity. 8, 74, 76, 77, 92, 100 The recent finding that humans express multiple isoforms that have different functional effects has added a new layer of complexity to this protein and much remains to be discovered about the function of the individual OPN isoforms in vascular physiology and pathophysiology, what mediates OPN splicing, and if specific isoforms are possible therapeutic targets. Indeed, it was shown recently that OPN isoforms are differentially upregulated in patients with end-stage heart failure, where OPNa was significantly upregulated in patients with dilated cardiomyopathy, whereas expression of OPNb and OPNc were only detected in patients with ischemic cardiomyopathy. 119 Therefore, additional studies are required to determine if individual OPN isoforms are better diagnostic or prognostic biomarkers of CVD severity than total OPN levels.
Substantial progress has been made recently toward our understanding of the biological functions of OPN in several vascular disease pathologies. The cellular sources of OPN have been identified, which has led to the discovery of many of its important cell-and tissue-type specific functions. Evidence presented in this review suggests that the role of OPN in vascular disease may follow the Goldilocks principle, with too little OPN impeding the tissue injury and wound healing responses, whereas too much OPN leads to deleterious vascular remodeling. We also require a better understanding of how specific vascular cell types differentially, post-translationally modify OPN and if and how these modifications vary with disease state. Additional work is also necessary to determine the underlying molecular mechanisms of OPN isoform-specific biologic functions. The future development of humanized transgenic animals and isoform-specific tools should greatly facilitate this work and will further our understanding of the physiological and pathophysiologic roles of these newly defined OPN splice variants. 
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